- A new study suggests that long COVID symptoms are unlikely caused by widespread brain inflammation.
- Researchers found no significant evidence of neuroinflammation in most patients with prolonged neurological and cognitive difficulties.
- The study found that debilitating symptoms in long COVID patients are associated with brain regions governing emotion and mood regulation.
- The findings indicate that long COVID’s neurological burden may stem from functional brain changes rather than ongoing inflammatory damage.
- The study’s results may reshape how clinicians approach diagnosis and treatment of long COVID.
Contrary to prevailing theories, a new neuroimaging study indicates that persistent long COVID symptoms are unlikely driven by widespread brain inflammation. Researchers found no significant evidence of neuroinflammation in the majority of patients experiencing prolonged neurological and cognitive difficulties following SARS-CoV-2 infection. Instead, the most debilitating symptoms — including fatigue, brain fog, and mood disturbances — were strongly associated with elevated activity in brain regions governing emotion and mood regulation, such as the amygdala and anterior cingulate cortex. These findings suggest that long COVID’s neurological burden may stem more from functional brain changes than from ongoing inflammatory damage, reshaping how clinicians might approach diagnosis and treatment.
No Widespread Neuroinflammation Detected on PET Scans
The study, published in the Journal of Neurology, utilized positron emission tomography (PET) scans to measure levels of translocator protein (TSPO), a biomarker indicative of microglial activation and neuroinflammation. Researchers examined 35 individuals with confirmed long COVID — defined as persistent symptoms lasting at least 12 weeks post-infection — and compared them with 20 fully recovered individuals and 18 healthy controls. Only two long COVID patients (approximately 6%) showed elevated TSPO binding, a rate statistically indistinguishable from the control groups. In contrast, 94% of long-haulers exhibited normal neuroinflammatory markers despite suffering from significant cognitive and affective symptoms. These results challenge the widely held assumption that lingering brain fog and fatigue are the result of unresolved immune activation in the central nervous system. The study’s lead author, Dr. Elena Martinez from University College London, stated, “Our data do not support the idea that chronic neuroinflammation is a common feature of long COVID.”
Key Players: Researchers, Patients, and the Medical Community
The research team, based at University College London and King’s College Hospital, collaborated with the UK’s National Institute for Health Research to recruit participants from long COVID clinics across London. Patients underwent rigorous clinical assessments, neuropsychological testing, and multimodal brain imaging. The inclusion criteria required documented SARS-CoV-2 infection and persistent symptoms such as concentration deficits, memory issues, depression, or anxiety. Notably, participants were selected to represent a spectrum of initial infection severity — from mild outpatient cases to those requiring hospitalization. The medical community has increasingly focused on neuroinflammation as a potential therapeutic target, with some clinics already trialing anti-inflammatory drugs like corticosteroids or monoclonal antibodies. However, this study’s findings suggest such interventions may be misdirected for most patients. Patient advocacy groups have welcomed the research, emphasizing that understanding the true mechanisms behind long COVID is essential for validating patient experiences and guiding effective care.
Trade-offs: Treatment Implications and Diagnostic Shifts
The absence of widespread neuroinflammation has significant implications for treatment strategies. If inflammation is not the primary driver, then immunosuppressive or anti-inflammatory therapies may offer limited benefit and could even pose unnecessary risks, such as increased susceptibility to infections or metabolic side effects. Conversely, the discovery of hyperactivity in emotion-processing brain networks points toward neuropsychiatric mechanisms — potentially involving dysregulation of the limbic system or autonomic nervous system. This opens the door for alternative interventions, including cognitive behavioral therapy, mindfulness-based stress reduction, or neuromodulation techniques like transcranial magnetic stimulation. However, such approaches must be carefully evaluated in controlled trials. A major trade-off lies in diagnostic clarity: while ruling out inflammation simplifies the biological model for many, it may inadvertently lead some clinicians to misinterpret symptoms as purely psychological. The study authors caution against this reductionist view, emphasizing that functional brain changes are neurologically real, even in the absence of structural damage.
Timing: Why This Study Changes the Conversation Now
This study arrives at a critical juncture in long COVID research, as global health systems grapple with an estimated 65 million affected individuals and mounting pressure to define biological underpinnings. Earlier small-scale studies had reported elevated inflammatory markers in cerebrospinal fluid or blood, fueling the neuroinflammation hypothesis. However, those findings were often inconsistent or based on indirect measures. The current research is among the first to use direct in vivo imaging of brain inflammation in a well-characterized long COVID cohort. Advances in PET imaging resolution and TSPO quantification methods have only recently made such precise assessments feasible. Moreover, with the acute phase of the pandemic receding, attention has rightly shifted to chronic sequelae. This study’s timing allows it to influence ongoing clinical trials and shape the next generation of long COVID research frameworks, steering focus toward functional neurology rather than immunology.
Where We Go From Here
In the next 6 to 12 months, three scenarios could unfold. First, clinical trials targeting neuroinflammation may be re-evaluated or repurposed, with sponsors redirecting resources toward neuropsychiatric interventions. Second, diagnostic protocols could begin incorporating functional brain imaging to identify patterns of neural dysregulation, improving patient stratification. Third, interdisciplinary clinics combining neurology, psychiatry, and rehabilitation may become the standard of care, reflecting a more integrated model of long COVID management. Each scenario depends on replication of these findings in larger, more diverse populations, including those from different ethnic and geographic backgrounds. International consortia such as the WHO’s Post-COVID-19 Clinical Network are already planning multicenter studies to validate these results. The path forward hinges on recognizing long COVID not as a single disease, but as a spectrum of post-viral syndromes with distinct — and treatable — mechanisms.
Bottom line — this study refutes the dominant theory that brain inflammation causes long COVID, instead revealing that symptom severity is linked to altered neural activity in emotional and cognitive circuits, urging a fundamental shift in research and treatment paradigms.
Source: MedicalXpress